Skip to main content

Table 1 Characteristics of the individual studies included in the meta-analysis

From: The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case–control studies

Author

Year

Country

Ethnicity

Cancer type

Genotyping method

Control

Cases/control

Cases

Control

HWE

NOS

aa

ag

gg

aa

ag

gg

Mackawy

2019

Egypt

Arabian

Ovarian carcinoma

PCR–RFLP

HB

50/20

14

20

16

4

6

10

0.128

6

Pei

2018

China

Asian

Acute lymphoblastic leukemia

PCR–RFLP

PB

266/266

55

144

67

53

150

63

0.035

7

Al Zoubi

2017

Italy

Caucasian

Breast cancer

Sequencing

HB

23/16

8

14

1

11

5

0

0.459

7

De Mattia

2017

Italy

Caucasian

Hepatocellular cancer

TaqMan

HB

192/192

128

52

12

137

49

5

0.806

7

Sarwar

2017

Pakistan

Asian

Thyroid cancer

ARMS-PCR

HB

456/400

289

90

77

297

65

38

 < 0.001

7

Yan

2016

China

Asian

Yhyroid carcinoma

PCR

HB

276/403

116

127

33

202

161

40

0.345

8

Zhu

2016

China

Asian

Bladder cancer

TaqMan

HB

184/260

72

53

59

69

142

49

0.111

7

Ali

2016

Saudi Arabia

Arabian

Breast cancer

PCR–RFLP

HB

143/145

102

40

1

93

28

24

 < 0.001

7

Chang

2015

China

Asian

Leiomyoma

PCR–RFLP

HB

166/474

35

91

40

93

268

113

0.004

7

Chen

2015

China

Asian

Lung cancer

PCR–RFLP

HB

358/716

70

202

86

147

395

177

0.007

7

Liu

2015

China

Asian

Nasopharyngeal carcinoma

PCR–RFLP

HB

176/880

33

99

44

179

489

212

0.001

7

Su

2015

China

Asian

Breast cancer

PCR–RFLP

HB

1232/1232

239

696

297

254

668

310

0.002

8

Al Zoubi

2015

Jordan

Arabian

Breast cancer

Sequencing

HB

46/31

16

28

2

21

9

1

0.976

7

Yuan

2015

China

Asian

Papillary thyroid cancer

PCR

HB

183/367

77

84

22

184

147

36

0.406

6

Goričar

2015

Slovenia

Caucasian

Acute lymphoblastic leukemia

TaqMan

PB

121/184

89

  

117

  

 ≥ 0.050

8

Goričar

2015

Slovenia

Caucasian

Osteosarcoma

TaqMan

PB

79/373

47

  

247

  

ND

7

Smolkova

2014

Germany

Caucasian

Acute lymphoblastic leukaemia

TaqMan

HB

460/547

286

155

19

340

183

24

0.921

7

TSAI

2014

China

Asian

Oral cancer

PCR–RFLP

HB

788/956

155

438

195

195

532

229

 < 0.001

7

He

2013

China

Asian

Lung cancer

PCR

HB

507/661

180

230

97

184

313

164

0.181

7

Zhao

2013

China

Asian

Glioma

TaqMan

HB

384/384

83

201

100

95

181

108

0.271

7

Gresner

2012

Poland

Caucasian

Head and neck cancer

PCR–RFLP

PB

81/100

45

31

5

59

34

7

0.497

8

VRAL

2011

Belgium

Caucasian

Breast cancer

PCR–RFLP or SnapShot technique

HB

343/172

220

108

15

117

52

3

0.304

5

Quaye

2009

mixed

Caucasian

Ovarian cancer

TaqMan

PB

1461/2307

940

484

37

1505

713

89

0.691

8

Andrew

2009

USA

Mixed

Bladder cancer

PCR–RFLP

PB

342/559

190

  

333

  

ND

7

Hayden

2007

Germany, Italy, Spain, Ireland,France, Czech Republic and the Irish

Caucasian

Myeloma

TaqMan

Mixed

302/257

189

100

13

153

91

13

0.911

8

Ni

2006

China

Asian

Thyroid carcinoma

PCR–RFLP

HB

191/201

66

81

44

62

94

45

0.411

7

Garcıa-Closas

2006

Poland

Caucasian

Breast cancer

ND

PB

1920/2218

1210

632

78

1386

736

96

0.891

8

Garcıa-Closas

2006

USA

Caucasian

Breast cancer

ND

PB

1564/1264

980

521

63

837

357

52

0.079

8

Wu

2006

USA

Mixed

Bladder cancer

PCR–RFLP

HB

599/595

402

185

12

398

185

12

0.072

8

Paul Pharoah ICRC-Thai

2006

Thailand

Asian

Breast cancer

ND

PB

465/389

153

217

95

135

182

72

0.441

8

Paul Pharoah SEARCH

2006

UK

Caucasian

Breast cancer

ND

PB

2790/3642

1808

889

93

2388

1113

141

0.427

8

Paul Pharoah Sheffield

2006

UK

Caucasian

Breast cancer

ND

HB

1185/1159

781

369

35

755

353

51

0.238

8

Paul Pharoah USRTS

2006

USA

Caucasian

Breast cancer

ND

Nested

718/1049

458

224

36

650

356

43

0.509

8

Auranen1

2005

US FROC

Caucasian

Ovarian cancer

TaqMan

PB

325/417

204

112

9

267

133

17

0.932

8

Auranen2

2005

UK RMH/YOV

Caucasian

Ovarian cancer

TaqMan

PB

301/1808

194

95

12

1196

535

77

0.083

8

Matullo

2005

Italy

Caucasian

Bladder cancer

PCR–RFLP

HB

316/315

207

98

11

201

102

12

0.833

7

Han

2004

USA

Caucasian

Breast cancer

TaqMan

PB

991/1291

630

322

39

865

372

54

0.084

8

Han

2004

USA

Caucasian

Endometrial cancer

TaqMan

PB

220/663

140

73

7

438

200

25

0.716

8

Jacobsen

2004

Denmark

Caucasian

Lung cancer

PCR

Nested

256/269

111

116

29

108

127

34

0.724

8

Tranah

2004

USA (NHS)

Caucasian

Colorectal adenoma

TaqMan

Nested

556/557

256

212

58

250

222

54

0.65

8

Tranah

2004

USA (HPFS)

Caucasian

Colorectal adenoma

TaqMan

Nested

376/725

180

155

31

329

303

73

0.793

8

Kuschel

2002

UK

Caucasian

Breast cancer

TaqMan

PB

1828/1808

1176

581

71

1196

535

77

0.083

8

Winsey

2000

UK

Caucasian

Melanoma skin cancer

PCR-SSP

HB

125/211

5

47

73

8

80

122

0.245

7